Six abstracts to be presented demonstrating efficacy and tolerability of investigational Bylvay in select cholestatic liver diseasesNew data emphasizes the consistent benefit of Bylvay as an. | May 17, 2023
Six abstracts to be presented demonstrating efficacy and tolerability of investigational Bylvay in select cholestatic liver diseasesNew data emphasizes the consistent benefit of Bylvay as an investigational
Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance Paris , 27 April 2023Ipsen , a global specialty-driven biopharmaceutical company,. | April 27, 2023
StockNews.com started coverage on shares of Albireo Pharma (NASDAQ:ALBO – Get Rating) in a research report released on Thursday. The firm issued a sell rating on the biopharmaceutical company’s stock. Other equities analysts have also issued reports about the company. Guggenheim lowered Albireo Pharma from a buy rating to a neutral rating in a research […]
Shares of Albireo Pharma, Inc. (NASDAQ:ALBO – Get Rating) have been assigned a consensus recommendation of “Hold” from the eight brokerages that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating on the […]